EUSA Pharma has announced the strengthening of its senior leadership team with the appointments of Carsten Thiel as president of europe and Darrel P. Cohen as head of clinical development.
Both Dr Thiel and Dr Cohen bring extensive senior level pharmaceutical company experience to these newly-created roles, and will lead EUSA’s growing commercial infrastructure in Europe and worldwide late-stage clinical development activities respectively.
Carsten Thiel brings 27 years’ commercial experience to EUSA gained in a variety of international roles in the pharmaceutical industry whilst Darrel P. Cohen is a hematologist and oncologist with 20 years’ clinical development experience in the pharmaceutical industry.
Lee Morley, EUSA Pharma’s chief executive officer, said, “We are delighted to welcome Carsten and Darrel to EUSA. Both bring significant experience, vision and proven executional skills to the Company, which will prove invaluable as we continue the rapid expansion in Europe, Emerging Markets and the United States. With the ongoing commercial roll out of Fotivda in Europe and Qarziba and Sylvant globally, and the ramping up of development activities targeting a number of additional indications for Sylvant and Qarziba, we look forward to our new colleagues contributing to EUSA’s ongoing success.”